Sunil Verma, MD

Dr. Verma Discusses Biosimilars for Trastuzumab

June 1st 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the potential role for trastuzumab (Herceptin) biosimilars.

Dr. Verma Discusses the Approval Process for Biosimilars

May 18th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the FDA approval process for biosimilars.

Dr. Verma on Immunotherapy in HER2+ Breast Cancer

May 14th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses immunotherapy in HER2-positive breast cancer.

Dr. Verma Discusses Challenges With Biosimilars in Oncology

May 8th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses challenges with integrating biosimilars into practice.

Dr. Verma Discusses Emerging Agents in HER2+ Breast Cancer

April 12th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses emerging agents for the treatment of HER2-positive breast cancer.

Dr. Verma Discusses Combinations With Biosimilars

April 4th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses the possibility of combining biosimilars.

Dr. Verma Discusses Biosimilars in the Oncology Sphere

March 27th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses biosimilars in the oncology sphere.

Dr. Verma on Incorporating Biosimilars Into Practice

March 13th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses incorporating biosimilars in oncology practice.

Dr. Verma on Treatments in the Neoadjuvant Setting of HER2-Positive Breast Cancer

October 13th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses the overall treatment paradigm in the neoadjuvant setting of HER2-positive breast cancer.

Dr. Sunil Verma on Treatment for Early HER2+ Breast Cancer

September 2nd 2016

Dr. Verma on Advancements in Treatment of HER2-Positive Breast Cancer

March 12th 2016

Sunil Verma, MD, department head, Clinical Department of Oncology, Calgary Zone, medical director, Tom Baker Cancer Centre, discusses recent advancements in the field of HER2-positive breast cancer.